MGNX.US MacroGenics Inc

Healthcare Biotechnology USA Stocks
2.20 USD
Close of Nov 15, 2026
1.32 5.08
Market cap
USD 141M
P/E
-
P/B
5.64x
ROE
-197.9%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 3 quarters up to Sep 2026.

Is MGNX.US undervalued?

Graham number

The Graham number of MacroGenics Inc cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

MacroGenics Inc fundamental analysis

No fundamental analysis for MacroGenics Inc yet.

MacroGenics Inc stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About MacroGenics Inc

MacroGenics, Inc., a clinical-stage biopharmaceutical company, discovers, develops, manufactures, and commercializes antibody-based therapeutics for the treatment of cancer in the United States. The company's product pipeline includes lorigerlimab, a bispecific DART molecule that targets checkpoint inhibitors PD-1 and CTLA-4 for the treatment of mCRPC and docetaxel that is in phase 2 clinical trials, as well as for the treatment of platinum-resistant ovarian cancer and clear…

Full company profile